Last reviewed · How we verify

NCT05969119

Addition of Pyridostigmine to Conventional Management of Postdural Puncture Headache

Completed Phase 4 Last updated 4 September 2024
What this trial tests

Phase 4 trial testing Pyridostigmine in Postdural Puncture Headache in 30 participants. Completed in 3 January 2024.

Timeline
25 July 2023
Primary endpoint
3 January 2024
3 January 2024

Quick facts

Lead sponsorAin Shams University
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date25 July 2023
Primary completion3 January 2024
Estimated completion3 January 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 20 to 40, any sex, with Postdural Puncture Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Postdural puncture headache (PDPH) is a major complication of neuraxial anesthesia that can occur following spinal anesthesia and with inadvertent Dural puncture during epidural anesthesia. The presence of Pyridostigmine in CSF would be expected to increase the level of acetylcholine in CSF and subsequently in the brain through inhibition of cholinesterase. The increased level of acetylcholine would produce cerebral vasoconstriction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pyridostigmine

Trials testing the same drug.

Other recruiting trials for Postdural Puncture Headache

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05969119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing